Creating master cell banks for new SARS-CoV-2 vaccines
Task V34: Master Cell Banks Manufacturing for Next Generation SARS-CoV-2 Vaccines
['FUNDING_OTHER'] · IDT BIOLOGIKA GMBH · NIH-11080845
This study is working on creating special cell banks to help make better vaccines for COVID-19, so that patients can have more effective protection against the virus and its variants.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | IDT BIOLOGIKA GMBH (nih funded) |
| Locations | 1 site (DESSAU-ROSSLAU, GERMANY) |
| Trial ID | NIH-11080845 on ClinicalTrials.gov |
What this research studies
This research focuses on developing master cell banks that are essential for manufacturing next-generation vaccines against SARS-CoV-2. It involves a comprehensive approach that includes product development planning, optimization, and compliant manufacturing processes for clinical studies. Patients may benefit from the development of more effective vaccines that can better protect against COVID-19 and its variants. The research also includes regulatory support to ensure that these vaccines meet safety and efficacy standards.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals at risk for COVID-19, particularly those in vulnerable populations or with underlying health conditions.
Not a fit: Patients who are not at risk for COVID-19 or those who have already received effective vaccinations may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective vaccines against SARS-CoV-2, enhancing public health and safety.
How similar studies have performed: Other research has shown success in developing vaccines using similar methodologies, particularly in response to infectious diseases.
Where this research is happening
DESSAU-ROSSLAU, GERMANY
- IDT BIOLOGIKA GMBH — DESSAU-ROSSLAU, GERMANY (ACTIVE)
Researchers
- Principal investigator: TRUSHEIM, HEIDI — IDT BIOLOGIKA GMBH
- Study coordinator: TRUSHEIM, HEIDI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Infectious Disease Pathway, Infectious Diseases, Infectious Disorder, Communicable Diseases